Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 54

1.

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.

Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, Graham J, Kirkbride P, Logue J, Malik Z, Money-Kyrle J, O'Sullivan JM, Panades M, Parker C, Patterson H, Scrase C, Staffurth J, Stockdale A, Tremlett J, Bidmead M, Mayles H, Naismith O, South C, Gao A, Cruickshank C, Hassan S, Pugh J, Griffin C, Hall E; CHHiP Investigators.

Lancet Oncol. 2016 Jun 20. pii: S1470-2045(16)30102-4. doi: 10.1016/S1470-2045(16)30102-4. [Epub ahead of print]

PMID:
27339115
2.

What approaches to social prescribing work, for whom, and in what circumstances? A protocol for a realist review.

Husk K, Blockley K, Lovell R, Bethel A, Bloomfield D, Warber S, Pearson M, Lang I, Byng R, Garside R.

Syst Rev. 2016 Jun 3;5(1):93. doi: 10.1186/s13643-016-0269-6.

3.

Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.

Wilkins A, Mossop H, Syndikus I, Khoo V, Bloomfield D, Parker C, Logue J, Scrase C, Patterson H, Birtle A, Staffurth J, Malik Z, Panades M, Eswar C, Graham J, Russell M, Kirkbride P, O'Sullivan JM, Gao A, Cruickshank C, Griffin C, Dearnaley D, Hall E.

Lancet Oncol. 2015 Dec;16(16):1605-16. doi: 10.1016/S1470-2045(15)00280-6. Epub 2015 Oct 28.

4.

A Multicenter Randomized Trial of Ibandronate Compared With Single-Dose Radiotherapy for Localized Metastatic Bone Pain in Prostate Cancer.

Hoskin P, Sundar S, Reczko K, Forsyth S, Mithal N, Sizer B, Bloomfield D, Upadhyay S, Wilson P, Kirkwood A, Stratford M, Jitlal M, Hackshaw A.

J Natl Cancer Inst. 2015 Aug 4;107(10). pii: djv197. doi: 10.1093/jnci/djv197. Print 2015 Oct.

PMID:
26242893
5.

Night time blood pressure dip.

Bloomfield D, Park A.

World J Cardiol. 2015 Jul 26;7(7):373-6. doi: 10.4330/wjc.v7.i7.373.

6.

Data mashups: potential contribution to decision support on climate change and health.

Fleming LE, Haines A, Golding B, Kessel A, Cichowska A, Sabel CE, Depledge MH, Sarran C, Osborne NJ, Whitmore C, Cocksedge N, Bloomfield D.

Int J Environ Res Public Health. 2014 Feb 4;11(2):1725-46. doi: 10.3390/ijerph110201725.

7.

Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer.

Molife LR, Omlin A, Jones RJ, Karavasilis V, Bloomfield D, Lumsden G, Fong PC, Olmos D, O'Sullivan JM, Pedley I, Hickish T, Jenkins P, Thompson E, Oommen N, Wheatley D, Heath C, Temple G, Pelling K, de Bono JS.

Future Oncol. 2014 Feb;10(2):219-31. doi: 10.2217/fon.13.250.

PMID:
24490608
8.

Pelvic radiculopathies, lumbosacral plexopathies, and neuropathies in oncologic disease: a multidisciplinary approach to a diagnostic challenge.

Brejt N, Berry J, Nisbet A, Bloomfield D, Burkill G.

Cancer Imaging. 2013 Dec 30;13(4):591-601. doi: 10.1102/1470-7330.2013.0052.

9.

MK-0448, a specific Kv1.5 inhibitor: safety, pharmacokinetics, and pharmacodynamic electrophysiology in experimental animal models and humans.

Pavri BB, Greenberg HE, Kraft WK, Lazarus N, Lynch JJ, Salata JJ, Bilodeau MT, Regan CP, Stump G, Fan L, Mehta A, Wagner JA, Gutstein DE, Bloomfield D.

Circ Arrhythm Electrophysiol. 2012 Dec;5(6):1193-201. doi: 10.1161/CIRCEP.111.969782. Epub 2012 Oct 11.

10.

Training in clinical oncology: results of the Royal College of Radiologists' survey of new consultants.

Benstead K, Gilson D, Hanna L, Radhakrishna G, McAleer J, Bloomfield D, Jyothirmayi R, Campbell A, Booth J.

Clin Oncol (R Coll Radiol). 2012 Dec;24(10):e143-8. doi: 10.1016/j.clon.2012.08.005. Epub 2012 Sep 13.

PMID:
22981545
11.

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial.

Dearnaley D, Syndikus I, Sumo G, Bidmead M, Bloomfield D, Clark C, Gao A, Hassan S, Horwich A, Huddart R, Khoo V, Kirkbride P, Mayles H, Mayles P, Naismith O, Parker C, Patterson H, Russell M, Scrase C, South C, Staffurth J, Hall E.

Lancet Oncol. 2012 Jan;13(1):43-54. doi: 10.1016/S1470-2045(11)70293-5. Epub 2011 Dec 12.

12.

Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia.

Dansky HM, Bloomfield D, Gibbons P, Liu S, Sisk CM, Tribble D, McKenney JM, Littlejohn TW 3rd, Mitchel Y.

Am Heart J. 2011 Oct;162(4):708-16. doi: 10.1016/j.ahj.2011.07.010. Epub 2011 Sep 1.

PMID:
21982664
13.

Impact of serial troponin release on outcomes in patients with acute heart failure: analysis from the PROTECT pilot study.

O'Connor CM, Fiuzat M, Lombardi C, Fujita K, Jia G, Davison BA, Cleland J, Bloomfield D, Dittrich HC, Delucca P, Givertz MM, Mansoor G, Ponikowski P, Teerlink JR, Voors AA, Massie BM, Cotter G, Metra M.

Circ Heart Fail. 2011 Nov;4(6):724-32. doi: 10.1161/CIRCHEARTFAILURE.111.961581. Epub 2011 Sep 6.

14.

First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015).

FAST Trialists group, Agrawal RK, Alhasso A, Barrett-Lee PJ, Bliss JM, Bliss P, Bloomfield D, Bowen J, Brunt AM, Donovan E, Emson M, Goodman A, Harnett A, Haviland JS, Kaggwa R, Morden JP, Robinson A, Simmons S, Stewart A, Sydenham MA, Syndikus I, Tremlett J, Tsang Y, Wheatley D, Venables K, Yarnold JR.

Radiother Oncol. 2011 Jul;100(1):93-100. doi: 10.1016/j.radonc.2011.06.026.

PMID:
21752481
15.

The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses.

Campbell HE, Epstein D, Bloomfield D, Griffin S, Manca A, Yarnold J, Bliss J, Johnson L, Earl H, Poole C, Hiller L, Dunn J, Hopwood P, Barrett-Lee P, Ellis P, Cameron D, Harris AL, Gray AM, Sculpher MJ.

Eur J Cancer. 2011 Nov;47(17):2517-30. doi: 10.1016/j.ejca.2011.06.019. Epub 2011 Jul 7.

PMID:
21741831
16.

The Cardiac Safety Research Consortium electrocardiogram warehouse: thorough QT database specifications and principles of use for algorithm development and testing.

Kligfield P, Green CL, Mortara J, Sager P, Stockbridge N, Li M, Zhang J, George S, Rodriguez I, Bloomfield D, Krucoff MW.

Am Heart J. 2010 Dec;160(6):1023-8. doi: 10.1016/j.ahj.2010.09.002. Review.

PMID:
21146653
17.

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial.

Ellis P, Barrett-Lee P, Johnson L, Cameron D, Wardley A, O'Reilly S, Verrill M, Smith I, Yarnold J, Coleman R, Earl H, Canney P, Twelves C, Poole C, Bloomfield D, Hopwood P, Johnston S, Dowsett M, Bartlett JM, Ellis I, Peckitt C, Hall E, Bliss JM; TACT Trial Management Group; TACT Trialists.

Lancet. 2009 May 16;373(9676):1681-92. doi: 10.1016/S0140-6736(09)60740-6.

18.

New precompetitive paradigms: focus on cardiac safety.

Finkle J, Bloomfield D, Uhl K, Sanhai W, Stockbridge N, Krucoff MW.

Am Heart J. 2009 May;157(5):825-6. doi: 10.1016/j.ahj.2009.02.021. No abstract available.

PMID:
19376307
19.

Treating IIA/B seminoma with combination carboplatin and radiotherapy.

Gilbert DC, Vanas NJ, Beesley S, Bloomfield D, Money-Kyrle J, Norman A, Dearnaley D, Horwich A, Huddart RA.

J Clin Oncol. 2009 Apr 20;27(12):2101-2; author reply 2102-3. doi: 10.1200/JCO.2008.21.5269. Epub 2009 Mar 16. No abstract available.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk